Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity
- 1 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (11), 5425-5433
- https://doi.org/10.1158/0008-5472.can-06-4431
Abstract
Daunorubicin is an anthracycline antibiotic agent used in the treatment of hematopoietic malignancies. Toxicities associated with this agent include myelosuppression and cardiotoxicity; however, the genes or genetic determinants that contribute to these toxicities are unknown. We present an unbiased genome-wide approach that incorporates heritability, whole-genome linkage analysis, and linkage-directed association to uncover genetic variants contributing to the sensitivity to daunorubicin-induced cytotoxicity. Cell growth inhibition in 324 Centre d' Etude du Polymorphisme Humain lymphoblastoid cell lines (24 pedigrees) was evaluated following treatment with daunorubicin for 72 h. Heritability analysis showed a significant genetic component contributing to the cytotoxic phenotypes (h2 = 0.18–0.63 at 0.0125, 0.025, 0.05, 0.1, 0.2, and 1.0 μmol/L daunorubicin and at the IC50, the dose required to inhibit 50% cell growth). Whole-genome linkage scans at all drug concentrations and IC50 uncovered 11 regions with moderate peak LOD scores (>1.5), including 4q28.2 to 4q32.3 with a maximum LOD score of 3.18. The quantitative transmission disequilibrium tests were done using 31,312 high-frequency single-nucleotide polymorphisms (SNP) located in the 1 LOD confidence interval of these 11 regions. Thirty genes were identified as significantly associated with daunorubicin-induced cytotoxicity (P ≤ 2.0 × 10−4, false discovery rate ≤ 0.1). Pathway and functional gene ontology analysis showed that these genes were overrepresented in the phosphatidylinositol signaling system, axon guidance pathway, and GPI-anchored proteins family. Our findings suggest that a proportion of susceptibility to daunorubicin-induced cytotoxicity may be controlled by genetic determinants and that analysis using linkage-directed association studies with dense SNP markers can be used to identify the genetic variants contributing to cytotoxicity. [Cancer Res 2007;67(11):5425–33]Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal CancerSeminars in Oncology, 2006
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced ApoptosisJournal of Biological Chemistry, 2005
- Corticosteroids Inhibit Cell Death Induced by Doxorubicin in Cardiomyocytes: Induction of Antiapoptosis, Antioxidant, and Detoxification GenesMolecular Pharmacology, 2005
- Anthracycline-Induced Cardiotoxicity in Children with CancerPediatric Drugs, 2005
- Genetic analysis of genome-wide variation in human gene expressionNature, 2004
- Decreased levels of topoisomerase IIα in human renal cell carcinoma lines resistant to etoposideZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Daunorubicin Activates NFκB and Induces κB-dependent Gene Expression in HL-60 Promyelocytic and Jurkat T Lymphoma CellsPublished by Elsevier ,1997
- Apoptosis of Lung Cancer Cells Caused by Some Anti-cancer Agents (MMC, CPT-11, ADM) is Inhibited by BCL-2Biochemical and Biophysical Research Communications, 1993
- Inhibition of protein kinase C by antineoplastic agents: Implications for drug resistanceBiochemical and Biophysical Research Communications, 1987